The Cure Parkinson’s Quarterly Research Grant supports innovative preclinical, clinical, and translational research aimed at slowing, stopping, or potentially reversing Parkinson’s disease. The programme funds high-impact projects with strong scientific merit and clear potential to progress toward human clinical trials within approximately five years.
About the Cure Parkinson’s Quarterly Research Grant Program
The Cure Parkinson’s Quarterly Research Grant is designed to accelerate the discovery and development of new treatments for Parkinson’s disease. It prioritizes research that can move beyond early-stage findings and contribute directly to clinical applications that may benefit people living with the condition. The programme operates on a quarterly funding cycle and uses a two-stage competitive application process with expert peer review.
Funding Size
- Funding up to £250,000 for preclinical research projects
- Additional support may be considered for clinical trials or related sub-studies
- Funding is aimed at projects with clear translational and clinical potential
- Projects are expected to demonstrate a pathway toward human trials within five years
Who Can Apply
- Academic and research institutions
- Biotechnology and pharmaceutical companies
- Independent researchers affiliated with eligible organisations
- International applicants are eligible
Applicants should demonstrate:
- Strong expertise in Parkinson’s disease or related neuroscience fields
- High-quality scientific and methodological design
- Clear translational pathway toward clinical application
- Strong justification of costs (especially for commercial entities)
Geographic Eligibility
- Open to applicants worldwide
- Encourages international and cross-institutional collaboration
- Projects may be conducted in any country, provided institutional and ethical standards are met
Sector or Thematic Focus
The programme supports research across three main areas:
Preclinical Research
- Laboratory-based studies
- Drug discovery and early development
- Mechanistic studies of disease progression
Clinical Research
- Human clinical trials and pilot studies
- Patient-focused therapeutic interventions
- Real-world testing of potential treatments
Translational Research
- Bridging laboratory discoveries to clinical use
- Developing pathways to human trials
- Advancing experimental therapies toward patient application
Read Also: UMass ADVANCE Faculty Fellows Program 2026 – Apply Now
Application Process
The application process follows a structured two-stage model:
Stage 1
- Submission of a short preliminary proposal
- Outline of research idea, objectives, and expected impact
- Initial assessment by expert reviewers
Stage 2 (by invitation only)
- Full research proposal submission
- Detailed methodology and study design
- Budget breakdown and justification
- Institutional approvals and supporting documentation
- Letter of support from host institution
Required Materials
- Stage 1 concept proposal
- Full CV or institutional profile
- Detailed research methodology (Stage 2)
- Budget and justification (Stage 2)
- Ethics and regulatory approvals (if applicable)
- Institutional letter of support (Stage 2)
Key Dates
- Application deadline: 22 June 2026
- Funding rounds: Quarterly
- Stage 2 invitations: After initial review
- Final decisions: Following peer review cycles
Read Also: The 2026 Façade Improvement Grant – Apply Now
Selection Notes
- Applications are assessed through independent expert peer review
- Strong emphasis is placed on translational potential and clinical relevance
- Projects without a clear pathway to human trials are less competitive
- Clinical proposals may include input from individuals with lived experience of Parkinson’s disease
- Funding decisions may include approval, revision requests, or rejection